A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2025, filed Aug 12, 2025. Each column of the statement tables below links to the filing it was taken from.
GB SCIENCES INC (GBLX) reported $0 in revenue for fiscal year 2024. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Expense-heavy operations and financing dependence defined the reported business, even before considering its weak liquidity position.
In FY2020, the net loss of$12.4M was far larger than operating activities’ cash consumption of$4.5M , indicating that accruals, impairments, or other non-cash items materially shaped earnings. A financing inflow of$5.0M offset only part of that cash use, so the reported loss and funding pattern point to different pressures on the business.
The cost structure overwhelmed the $3.1M revenue base: selling, general and administrative expense reached
The balance sheet was already tightly financed in FY2020: liabilities nearly matched assets at
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
GB SCIENCES INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
GB SCIENCES INC generated $97K in revenue in Q3 2025.
GB SCIENCES INC's EBITDA was -$67K in Q3 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 71.5% from the same quarter a year earlier. Against the prior quarter it is up 57.8%.
GB SCIENCES INC reported -$100K in net income in Q3 2025. This represents an increase of 46.4% from the same quarter a year earlier. Against the prior quarter it is up 47.3%.
Not reported for Q3 2025.
Cash & Balance Sheet
GB SCIENCES INC held $3K in cash as of Q3 2025; long-term debt is not reported for that period.
Not reported for Q3 2025.
Not reported for Q3 2025.
Margins & Returns
GB SCIENCES INC's gross margin was 100.0% in Q3 2025, indicating the percentage of revenue retained after direct costs.
GB SCIENCES INC's operating margin was -68.5% in Q3 2025, reflecting core business profitability.
Not shown for Q3 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q3 2025.
Capital Allocation
None of these metrics is reported for Q3 2025.
GBLX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $97K | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Cost of Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Gross Profit | $97K | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| SG&A Expenses | $164K-30.0% | $158K-71.4% | $254K-4.1% | N/A | $234K-42.5% | $551K+99.9% | $265K-42.3% | N/A |
| Operating Income | -$67K+71.5% | -$158K+71.4% | -$254K+4.1% | N/A | -$234K+42.5% | -$551K-99.9% | -$265K+42.3% | N/A |
| EBITDA | -$67K+71.5% | -$158K+71.4% | -$254K+3.9% | N/A | -$234K+39.4% | -$551K-115.9% | -$264K+39.8% | N/A |
| Interest Expense | $34K-11.8% | $33K-23.4% | $31K-24.3% | N/A | $38K-7.7% | $43K+14.8% | $41K+5.8% | N/A |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$100K+46.4% | -$191K+56.1% | -$285K-4.4% | N/A | -$187K+58.3% | -$434K-38.7% | -$273K+45.2% | N/A |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00+100.0% | $0.00 | $0.00 | $0.00 | -$0.010.0% |
Not reported in any period shown, so not listed: R&D Expenses, EPS (Diluted), Diluted Shares (Avg).
GBLX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $94K-35.8% | $94K-60.0% | $91K-60.1% | $103K-70.6% | $147K-58.2% | $234K-92.5% | $229K-90.2% | $352K-86.2% |
| Current Assets | $94K-35.8% | $94K-60.0% | $91K-60.1% | $103K-66.6% | $147K-52.5% | $234K-73.3% | $229K+107.7% | $310K-5.6% |
| Cash & Equivalents | $3K-82.7% | $2K-97.8% | $0-100.0% | $12K-89.1% | $17K-84.1% | $105K-84.1% | $30K-45.1% | $110K-53.0% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $6.0M+19.6% | $5.9M+19.2% | $5.7M+15.7% | $5.4M+13.8% | $5.0M+4.9% | $4.9M+14.3% | $4.9M+9.0% | $4.8M+9.9% |
| Current Liabilities | $5.4M+10.1% | $5.4M+12.1% | $5.4M+9.7% | $5.1M+7.1% | $4.9M+3.4% | $4.9M+18.6% | $4.9M+18.9% | $4.8M+20.9% |
| Non-Current Liabilities | $557K+642.7% | $432K+476.0% | $322K+1188.0% | $322K | $75K | $75K-65.8% | $25K-93.7% | $0-100.0% |
| Total Equity | -$5.9M-21.3% | -$5.8M-23.2% | -$5.6M-19.4% | -$5.3M-20.6% | -$4.8M-10.0% | -$4.7M-293.3% | -$4.7M-116.1% | -$4.4M-147.2% |
| Retained Earnings | -$110.6M-1.0% | -$110.5M-1.0% | -$110.4M-1.3% | -$110.1M-1.3% | -$109.6M-0.8% | -$109.4M-3.8% | -$109.0M-3.7% | -$108.7M-3.9% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
GBLX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$124K+39.5% | -$108K+73.9% | -$22K+79.1% | -$252K-14.8% | -$205K+48.6% | -$413K+33.0% | -$105K+63.9% | -$220K+66.9% |
| Depreciation & Amortization | $0 | $0 | $0-100.0% | $0 | $0-100.0% | $0-100.0% | $624-96.9% | $0-100.0% |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | N/A |
| Investing Cash Flow | $0-100.0% | N/A | N/A | $0 | $85K+6491.0% | N/A | N/A | $0+100.0% |
| Financing Cash Flow | $125K+275.0% | $110K-56.4% | $10K-60.0% | $247K+342.9% | $33K+95.8% | $252K-79.8% | $25K-77.7% | $56K+111.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
GBLX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -68.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -103.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -106.2%+21.1pp | -203.2%-17.8pp | -311.7%-192.5pp | N/A | -127.3%+0.1pp | -185.4%-175.4pp | -119.2%-97.9pp | N/A |
| Current Ratio | 0.020.0x | 0.020.0x | 0.020.0x | 0.020.0x | 0.030.0x | 0.05-0.2x | 0.050.0x | 0.070.0x |
| Asset Turnover | 1.03+1.0x | 0.000.0x | 0.000.0x | N/A | 0.000.0x | 0.000.0x | 0.000.0x | N/A |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Note: Shareholder equity is negative (-$5.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GB SCIENCES INC GBLX | FY2024 | $0 | N/A | N/A | $81K | — |
| Adhera Therapeutics Inc ATRX | FY2022 | N/A | N/A | N/A | $72K | — |
| U S Stem Cell Inc USRM | FY2022 | $82K | N/A | N/A | $64K | — |
| Syros Pharmaceut SYRS | FY2023 | $9.9M | -$164.6M | N/A | $3.1M | — |
Where GB SCIENCES INC Ranks
Frequently Asked Questions
What is GB SCIENCES INC's annual revenue?
GB SCIENCES INC (GBLX) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What are GB SCIENCES INC's total assets?
GB SCIENCES INC (GBLX) had $103K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does GB SCIENCES INC spend on research and development?
GB SCIENCES INC (GBLX) invested $262K in research and development during fiscal year 2024.
What is GB SCIENCES INC's current ratio?
GB SCIENCES INC (GBLX) had a current ratio of 0.02 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is GB SCIENCES INC's P/E ratio?
GB SCIENCES INC (GBLX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $81K as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GB SCIENCES INC's price-to-sales ratio?
GB SCIENCES INC (GBLX) has no price-to-sales ratio at the moment: revenue is not positive (FY2024). The market capitalization is $81K as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is GB SCIENCES INC's debt-to-equity ratio negative or not reported?
GB SCIENCES INC (GBLX) has negative shareholder equity of -$5.3M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.